These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11726138)

  • 1. A stable single-chain variable fragment expressing transfectoma demonstrates induction of idiotype-specific cytotoxic T-cells during early growth stages of a murine B-lymphoma.
    Laxmanan S; Stuart GW; Ghosh SK
    Cancer Immunol Immunother; 2001 Oct; 50(8):437-44. PubMed ID: 11726138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of syngeneic cytotoxic T lymphocytes against a B cell tumor. III. MHC class I-restricted CTL recognizes the processed form(s) of idiotype.
    Chakrabarti D; Ghosh SK
    Cell Immunol; 1992 Oct; 144(2):455-64. PubMed ID: 1394454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of syngeneic cytotoxic T lymphocytes against a B cell tumor. II. Characterization of anti-idiotypic CTL lines and clones.
    Chakrabarti D; Ghosh SK
    Cell Immunol; 1992 Oct; 144(2):443-54. PubMed ID: 1394453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of syngeneic cytotoxic T lymphocytes against a B cell tumor. I. Role of idiotypic immunoglobulin.
    Chakrabarti D; Ghosh SK
    Cell Immunol; 1992 Jun; 142(1):54-66. PubMed ID: 1586959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoregulation by processed immunoglobulin on B-cells.
    Ghosh SK; Chakrabarti D
    Indian J Biochem Biophys; 1993 Dec; 30(6):414-21. PubMed ID: 7911781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.
    Armstrong AC; Dermime S; Allinson CG; Bhattacharyya T; Mulryan K; Gonzalez KR; Stern PL; Hawkins RE
    J Immunol; 2002 Apr; 168(8):3983-91. PubMed ID: 11937555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-lymphoma immunity: relative efficacy of peptide and recombinant DNA vaccine.
    Lim SY; Laxmanan S; Stuart G; Ghosh SK
    Cancer Detect Prev; 2001; 25(5):470-8. PubMed ID: 11718453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-4 is effective in restoring cytotoxic T cell activity that declines during in vivo progression of a murine B lymphoma.
    Santra S; Ghosh SK
    Cancer Immunol Immunother; 1997 Jul; 44(5):291-300. PubMed ID: 9247564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.
    Haynes NM; Trapani JA; Teng MW; Jackson JT; Cerruti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
    Blood; 2002 Nov; 100(9):3155-63. PubMed ID: 12384413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCL1 lymphoma protection induced by idiotype DNA vaccination is entirely dependent on anti-idiotypic antibodies.
    Cesco-Gaspere M; Benvenuti F; Burrone OR
    Cancer Immunol Immunother; 2005 Apr; 54(4):351-8. PubMed ID: 15692846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
    Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
    Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A genetic approach to idiotypic vaccination for B cell lymphoma.
    Stevenson FK; Zhu D; King CA; Ashworth LJ; Kumar S; Thompsett A; Hawkins RE
    Ann N Y Acad Sci; 1995 Nov; 772():212-26. PubMed ID: 8546396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GD2 oligosaccharide: target for cytotoxic T lymphocytes.
    Zhao XJ; Cheung NK
    J Exp Med; 1995 Jul; 182(1):67-74. PubMed ID: 7540657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant vaccinia viruses expressing immunoglobulin variable regions efficiently and selectively protect mice against tumoral B-cell growth.
    BenAmmar-Ceccoli S; Humblot S; Crouzier R; Acres B; Kieny MP; Herlyn D; Pasquali JL; Martin T
    Cancer Gene Ther; 2001 Oct; 8(10):815-26. PubMed ID: 11687905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. H-2-linked Ir gene control of VH determinant(s)-specific helper T cells.
    Kawahara DJ; Marrack P; Kappler JW
    J Mol Cell Immunol; 1986; 2(5):255-64. PubMed ID: 2978232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idiotype-specific T lymphocytes. I. Regulation of antibody production by idiotype-specific H-2-restricted T lymphocytes.
    Yamamoto H; Bitoh S; Torii M; Fujimoto S
    J Immunol; 1983 Mar; 130(3):1038-42. PubMed ID: 6185567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major histocompatibility complex class I-restricted presentation of influenza virus nucleoprotein peptide by B lymphoma cells harboring an antibody gene antigenized with the virus peptide.
    Billetta R; Filaci G; Zanetti M
    Eur J Immunol; 1995 Mar; 25(3):776-83. PubMed ID: 7705408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the idiotypic network in tumor immunity.
    Raychaudhuri S; Saeki Y; Chen JJ; Kohler H
    J Immunol; 1987 Dec; 139(11):3902-10. PubMed ID: 2824616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis of mousepox in H-2(d) mice: evidence for MHC class I-restricted CD8(+) and MHC class II-restricted CD4(+) CTL antiviral activity in the lymph nodes, spleen and skin, but not in the conjunctivae.
    Cespedes IS; Toka FN; Schollenberger A; Gieryńska M; Niemiałtowski M
    Microbes Infect; 2001 Nov; 3(13):1063-72. PubMed ID: 11709286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoreactive responses to an environmental factor. 2. Phthalate-induced anti-DNA specificity is downregulated by autoreactive cytotoxic T cells.
    Lim SY; Ghosh SK
    Immunology; 2004 May; 112(1):94-104. PubMed ID: 15096189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.